Acquired von Willebrand’s Syndrome in the Course of Waldenström’s Disease

 

PDF Download Buy Article Permissions and Reprints

Summary

Acquired von Willebrand's syndrome with a regressive evolution is described in a 66 year old man with Waldenström's disease. An inhibitor electively directed against Ristocetin cofactor activity has been demonstrated, active in vitro after incubation at 37° C. Serum fractionation showed that the inhibitor was independant of the monoclonal IgM and subsequent purification that it was IgG in nature. The results permit its classification as an auto-antibody.

• References

• 1 Simone JV, Comet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31: 806-812
  PubMedGoogle Scholar
• 2 Veltkamp JJ, Stevens P, Plas MVD, Loeliger EA. Production site of bleeding factor (acquired morbus von Willebrand). Thromb Diath Haemorrh 1970; 23: 412
  PubMedGoogle Scholar
• 3 Ingram GI, Kingston PS, Leslie J, Bowie EJ. Four cases of acquired von Willebrand's syndrome. Br J. Haematol 1971; 21: 189-199
  CrossrefPubMedGoogle Scholar
• 4 Poole-Wilson PA. Acquired von Willebrand's syndrome and systemic lupus erythematosus. Proc Soc Med 1972; 65: 7-8
  PubMedGoogle Scholar
• 5 Meyer D, Jenkins CS, Dreyfus MD, Fressinaud E, Larrieu MJ. Willebrand factor and Ristocetin. Br J Haematol 1974; 28: 579-599
  CrossrefPubMedGoogle Scholar
• 6 Mant MJ, Hirsh J, Gauldie J, Bienenstock J, Pineo GF, Luke KH. Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammapathy. Blood 1973; 42: 429-436
  PubMedGoogle Scholar
• 7 Leone G, Pola P, Guerrera G, Bizzi B. Acquired von Willebrand's syndrome during collagen disorder. Haematologica 1974; 59: 212-220
  PubMedGoogle Scholar
• 8 Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976; 48: 393-406
  PubMedGoogle Scholar
• 9 Wautier JL, Levy-Toledano S, Caen J. Acquired von Willebrand's syndrome and thrombopathy in a patient with chronic lymphocytic leukaemia. Scand J Haemat 1976; 16: 128-134
  PubMedGoogle Scholar
• 10 Stableforth P, Tamagnini GL, Dormandy KM. Acquired von Willebrand's syndrome with inhibitors both to factor VIII clotting activity and Ristocetin induced platelet aggregation. Br J Haematol 1976; 33: 565-573
  CrossrefPubMedGoogle Scholar
• 11 Rosborough TK, Swaim WR. Acquired von Willbrand's disease, platelet release defect and angiodysplasia. Am J Med 1978; 65: 96-100
  CrossrefPubMedGoogle Scholar
• 12 Joist JH, Cowan JF, Zimmerman TS. Acquired von Willebrand's disease. New Engl J Med 1978; suppl 7: 988-991
  PubMedGoogle Scholar
• 13 Gazengel C, Prieur AM, Jacques C, Buriot D, Nedellec J, Josso F. Antibody-induced von Willebrand's syndrome inhibition of VIII: VWF and VIII: AGN with sparing of VIII: AHF by the autoantibody. Am J Hematol 1978; 5: 355-363
  CrossrefPubMedGoogle Scholar
• 14 Zettervall I, Nilsson IG. Acquired von Willebrand's disease caused by a monoclonal antibody. Acta Med Scand 1978; 204: 521-528
  PubMedGoogle Scholar
• 15 Clough V, Mac Farlane IA, O'Connor J, Wood JK. Acquired Willebrand's syndrome and Ehlers-Danlos syndrome presenting with gastro-intestinal bleeding. Scand J Haematol 1979; 22: 305-310
  PubMedGoogle Scholar
• 16 Caen J, Larrieu MJ, Samama M. In: L'hémostase. Expansion scientifique, 2é ed 1975
  PubMed
• 17 Soulier JP, Larrieu MJ. Nouvelle méthode de diagnostic de l'hémophilie. Dosage des fractions antihémophiliques A et B Sang 1953; 205-215
  PubMedGoogle Scholar
• 18 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
  CrossrefPubMedGoogle Scholar
• 19 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l'antigéne lié au facteur VIII par la technique ELISA. Path Biol 1977; Suppl 25: 18-24
  PubMedGoogle Scholar
• 20 Sultan Y, Rossi J. Méthode de mesure de l'activité Willebrand sur plaque de microtitration. Nou Presse Méd 1977; 6: 44-46
  PubMedGoogle Scholar
• 21 Kasper CK. et al A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh (Stutt.) 1975; 34: 869-872
  PubMedGoogle Scholar
• 22 Webb AJ. A 30 minute preparative method for isolation of IgG from human serum. Vox Sang 1972; 23: 279-290
  CrossrefPubMedGoogle Scholar
• 23 Ouchterlony Ö. Diffusion-in-gel methods for immunological analysis. Progr Allergy 1958; 5: 1-78
  PubMedGoogle Scholar
• 24 Hoyer LM. Von Willebrand's disease. Sem Thromb Hemostas 1975; 2: 231-287
  PubMedGoogle Scholar
• 25 Meyer D, Frommel D, Larrieu MJ, Zimmerman TS. Selective absence of large forms of factor VIII/Von Willebrand factor in acquired von Willebrand's syndrome. Response to transfusion. Blood 1979; 54: 600-606
  PubMedGoogle Scholar
• 26 Brody JI, Haidar ME, Rossman RE. A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII. New Engl J Med 1970; 300: 408-410
  PubMedGoogle Scholar
• 27 Seligmann H, Brouet JC. Antibody activity of human myeloma globulins. Seminars in Hematology 1973; 10: 163-177
  PubMedGoogle Scholar
• 28 Parquet-Gernez A, Kacem M. Thrombopathies des dysglobulinémies. Nou Rev Fr Hématol 1976; 16: 437-442
  PubMedGoogle Scholar